D2 vs D3 Lymph Node Dissection for Left Colon Cancer (DILEMMA)
Colon Cancer
About this trial
This is an interventional treatment trial for Colon Cancer focused on measuring D2, D3, lymph node dissection, complete mesocolic excision, left colon cancer, CME
Eligibility Criteria
Inclusion Criteria:
- Agreement of the patient to participate in trial
- Colon cancer (only adenocarcinoma )
- The tumor located between the splenic flexure and rectosigmoid junction
- cT3-Т4а,b
- cN0-2
- cM0
- Tolerance of chemotherapy
- ASA 1-3
Exclusion Criteria:
- сТis - Т2, сТ4b (tail of the pancreas, stomach, small bowel, ureter, urinary bladder)
- Preoperative complications of the tumor (perforation and full bowel 3. obstruction)
- Previous radiotherapy or chemotherapy
- Synchronous or metachronous tumors
- Women during Pregnancy or breast feeding period
Sites / Locations
- Clinic of coloproctology and minimally invasive surgeryRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
D2 lymph node dissection
D3 lymph node dissection
For tumours in splenic flexure and proximal and mid part of descending colon lymph nodes 232 and 231 will be removed. For tumours in distal part of descending colon and proximal sigmoid lymph nodes 231, 232 and partially 241, 242 (considering variation of the feeding artery) will be removed. For tumours in the mid part of sigmoid colon lymph nodes 241, 242 will be removed. For tumours in the rectosigmoid junction 251, 252 groups of the lymph node will be removed.
For tumours in splenic flexure and proximal and mid part of descending colon lymph nodes 232, 231 and 253 will be removed. For tumours in distal part of descending colon and proximal sigmoid lymph nodes 231, 232 and 253 and partially 241, 242 (considering variation of the feeding artery) will be removed. For tumours in the mid part of sigmoid colon lymph nodes 241, 242 and 253 will be removed. For tumours in the rectosigmoid junction 251, 252 and 253 groups of the lymph node will be removed.